2021
DOI: 10.1016/j.esmoop.2021.100078
|View full text |Cite|
|
Sign up to set email alerts
|

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Abstract: Background: To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) 50% advanced nonsmall-cell lung cancer (aNSCLC) treated with first-line immunotherapy. Methods: Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis of 784 patients divided between statistically powered training (n ¼ 201) and validation (n ¼ 583) cohorts. Cutoff… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
55
0
2

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 47 publications
(59 citation statements)
references
References 30 publications
2
55
0
2
Order By: Relevance
“…The aim of this study was to evaluate the impact of concomitant baseline medications postulated to affect responsiveness to pembrolizumab monotherapy in a cohort of patients with metastatic NSCLC with a PD-L1 expression ≥50% treated with first-line pembrolizumab monotherapy outside clinical trials. [12][13][14][15][16] In total, 31 institutions participated to the study (online supplemental table S1) and retrospectively included patients treated from January 2017 to May 2020. We accrued a second cohort of metastatic epidermal growth factor receptor wild type patients with NSCLC treated with first-line chemotherapy as part of routine clinical practice from January 2013 to May 2020, across 13 out of the 31 above-mentioned institutions.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…The aim of this study was to evaluate the impact of concomitant baseline medications postulated to affect responsiveness to pembrolizumab monotherapy in a cohort of patients with metastatic NSCLC with a PD-L1 expression ≥50% treated with first-line pembrolizumab monotherapy outside clinical trials. [12][13][14][15][16] In total, 31 institutions participated to the study (online supplemental table S1) and retrospectively included patients treated from January 2017 to May 2020. We accrued a second cohort of metastatic epidermal growth factor receptor wild type patients with NSCLC treated with first-line chemotherapy as part of routine clinical practice from January 2013 to May 2020, across 13 out of the 31 above-mentioned institutions.…”
Section: Methodsmentioning
confidence: 99%
“…Detailed methodology regarding clinical outcomes estimation can be found elsewhere. [12][13][14][15][16] Data cut-off period was September 2020.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…In particular, within the high PD-L1 range, it could be useful to assess the value of PD-L1 as a prognostic marker together with clinical features based on recent evidence [23]. Moreover, recent retrospective studies identified the negative prognostic role of high neutrophil to lymphocyte ratio (NLR, with different cut-offs), as well as albumin and lactate dehydrogenase in blood, and included it into prognostic models in addition to clinical features including ECOG PS, steroid use, metastatic sites in patients receiving ICIs [8,24,25]. However, biomarker assessment was not included in our study, as it was designed to specifically evaluate clinical features that are routinely used in clinical practice for patient evaluation and treatment selection.…”
Section: Discussionmentioning
confidence: 99%